New hope for tough lymphomas: GNC-038 trial underway
NCT ID NCT05627856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called GNC-038 in people with certain types of lymphoma that have come back or stopped responding to treatment. The main goals are to find safe dose levels and see if the drug can shrink tumors. The trial is for adults aged 18 to 75 with NK/T-cell lymphoma or related blood cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a MALT1 blocker tame Hard-to-Treat lymphoma?